Caribou Property
VC Fund
Caribou Property is an investment firm.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Caribou Property invests in
Stages Caribou Property invests in
Countries Caribou Property invests in
Investment Focus
Industry
- Biotechnology 4 (100%)
- Therapeutics 3 (75%)
- Genetics 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
Stage
- Seed 1 (25%)
- Series B 1 (25%)
- Funding Round 1 (25%)
- Venture - Series Unknown 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M / Series B / Mar 02, 2022 | |
Macomics
|
Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. | $5.9M / Seed / Jul 29, 2021 | |
Lunac Therapeutics
|
Epidarex Capital invests in early-stage, high growth life science and health technology Epidarex Capital is a transatlantic venture fund that invests in early-stage, high growth life science and health technology companies in under-ventured markets. | $6.7M / Venture - Series Unknown / May 17, 2021 | |
Edinburgh Molecular Imaging
|
Edinburgh Molecular Imaging, a Scottish (UK) developer of optical molecular imaging technology. EM Imaging was founded in 2014 by an experienced team of scientists & clinicians. Together they have raised over £15 Million in non-dilutive funding from the Wellcome Trust, EPSRC and MRC to develop a unique range of SMART Agents that enablereal-time molecular imaging for the diagnosis of a variety of disease states.The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging agents. | $3.9M / Dec 17, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Caribou Property invest in?
Caribou Property invests primarily in Biotechnology, Therapeutics and Genetics startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Caribou Property last invest?
The most recent investment recorded for Caribou Property closed in Mar 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
